Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

Richard A. Adams, David J. Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D. Richman, Philip Quirke, Rachel Butler, Ewan Brown, Fiona Collinson, Stephen Falk, Harpreet Wasan, Kai-Keen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Louise C. Brown* (Corresponding Author)Timothy S. Maughan, FOCUS Trial Collaboration

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial'. Together they form a unique fingerprint.

Medicine & Life Sciences